VistaGen Therapeutics Inc (VTGN)

[MissionIR]

Thank you, as you indicated, the potential of VistaGen's technology relative to the current market value is astonishing. As of August 22, 2011, approximately 15.2 million shares were outstanding for a market cap of $32.7 Million (at $2.15 per share). Cutting only 10% of the development costs for one drug could potentially save as much as $170 million; not to mention the hundreds of millions of revenues potentially unlocked by rescuing a "shelved" candidate.